{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T22:56:36Z","timestamp":1757631396342,"version":"3.44.0"},"reference-count":36,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2025,8,3]],"date-time":"2025-08-03T00:00:00Z","timestamp":1754179200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vox Sanguinis"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background and Objectives<\/jats:title><jats:p>Many transfusion centres no longer perform an antiglobulin crossmatch on patients without clinically significant red cell alloantibodies, but instead use an abbreviated crossmatch. This policy brings many benefits but has an acknowledged risk of haemolytic transfusion reactions (HTRs). Historical estimates of reactions caused by undetected antibodies to low\u2010incidence antigens (LIAs) were in the region of 1 reaction per 500,000 red cell transfusions. This meta\u2010analysis of haemovigilance reports compares historical estimates with recorded events.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and Methods<\/jats:title><jats:p>This study analysed 255 acute HTR (AHTR) and 385 delayed HTR (DHTR) published in haemovigilance reports from four countries between 2006 and 2022.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The rate of HTRs (acute + delayed) per 100,000 red cells issued\/transfused varied from 0.75 to 4.46 by country. The majority of antibodies (59.6%) causing AHTRs were uncharacterized. Antibodies to LIAs accounted for 12.5% (<jats:italic>n<\/jats:italic>\u2009=\u200932) of AHTRs, and of these, 59.4% (<jats:italic>n<\/jats:italic>\u2009=\u200919) were identified as anti\u2010Wr<jats:sup>a<\/jats:sup> (DI3 in the Diego system). Of note was one fatal reaction likely attributable to anti\u2010Wr<jats:sup>a<\/jats:sup>. Antibodies to LIAs accounted for only 1.6% of DHTRs, where antibodies from other blood group systems were responsible, notably in the Rh and Kidd systems.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The risk of HTRs caused by undetected antibodies to LIAs calculated in this study is in the region of 1 reaction per 1 million red cell transfusions.<\/jats:p><\/jats:sec>","DOI":"10.1111\/vox.70068","type":"journal-article","created":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T00:14:57Z","timestamp":1754266497000},"page":"928-934","source":"Crossref","is-referenced-by-count":0,"title":["Analysis of haemovigilance reports reveals 12.5% of acute haemolytic transfusion reactions are attributed to antibodies to low\u2010incidence antigens"],"prefix":"10.1111","volume":"120","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-1371-7745","authenticated-orcid":false,"given":"Holly Elizabeth","family":"Perry","sequence":"first","affiliation":[{"name":"Department of Medical Laboratory Science University of Otago  Dunedin New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William Nicholas Charles","family":"Perry","sequence":"additional","affiliation":[{"name":"Department of Medical Laboratory Science University of Otago  Dunedin New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,8,3]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1751-2824.2011.01499.x"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/vox.12003"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.4103\/ajts.ajts_138_20"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.4274\/tjh.galenos.2022.2022.0284"},{"key":"e_1_2_9_6_1","unstructured":"Bundes\u00e4rztekammer Paul\u2010Ehrlich\u2010Institut.Richtlinie zur Gewinnung von Blut und Blutbestandteilen und zur Anwendung von Blutprodukten (H\u00e4motherapie). Germany. Available from:https:\/\/www.bundesaerztekammer.de\/fileadmin\/user_upload\/BAEK\/Themen\/Medizin_und_Ethik\/Richtlinie\u2010Haemotherapie\u20102023_neu2.pdf. Last accessed 8 May 2025."},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-3148.2000.00274.x"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2009.03.013"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.2003.00492.x"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/71.5.578"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1978.18278160574.x"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.3109\/00313028509105506"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1982.22282177114.x"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/82.2.178"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.2003.t01-1-00435.x"},{"key":"e_1_2_9_16_1","unstructured":"ANZSBT.Guidelines for Transfusion and Immunohaematology Laboratory Practice. Available from:https:\/\/anzsbt.org.au\/guidelines-standards\/anzsbt-guidelines. Last accessed 6 Nov 2024."},{"key":"e_1_2_9_17_1","unstructured":"NHS Blood and Transplant.Blood Essentials. Available from:https:\/\/nhsbtdbe.blob.core.windows.net\/umbraco\u2010assets\u2010corp\/33257\/blood\u2010essentials\u2010v1\u2010april\u20102024.pdf. Last accessed 6 Nov 2024."},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.2009.01278.x"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.4103\/0973-6247.83242"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000016703"},{"volume-title":"Blood transfusion guideline","year":"2011","author":"Haas F","key":"e_1_2_9_21_1"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.3925\/jjtc.70.7"},{"volume-title":"Guidelines for the transfusion of red cells","year":"2007","author":"Superior Health Council","key":"e_1_2_9_23_1"},{"key":"e_1_2_9_24_1","unstructured":"BekkersJA vanBohemen\u2010OnnesMR BrandA vanDuijnhovenJLP HaasFJLM vanKampIL et al.TRIP Annual Report 2011. Hemovigilance Extended Version. Available from:https:\/\/www.tripnet.nl\/pages\/en\/documents\/TRIP2011HemovigilanceExtendedversion.pdf. Last accessed 9 Jan 2025."},{"key":"e_1_2_9_25_1","first-page":"32","article-title":"Unlikely but not mission impossible \u2013 haemolytic transfusion reactions due to antibodies low to incidence antigens","volume":"33","author":"Tomlinson T","year":"2023","journal-title":"Transfus Med"},{"volume-title":"The blood group antigen factsbook","year":"2012","author":"Reid ME","key":"e_1_2_9_26_1"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2005.00196.x"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3148.1996.tb00096.x"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1159\/000488863"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.21307\/immunohematology-2021-005"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/vox.12367"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.15654"},{"key":"e_1_2_9_33_1","unstructured":"Directorate\u2010General for Health and Food Safety.Summary of the 2022 (2021 Data) Annual Reporting of Serious Adverse Reactions and Events for Blood and Blood Components. Available from:https:\/\/health.ec.europa.eu\/publications\/summary\u20102022\u20102021\u2010data\u2010annual\u2010reporting\u2010serious\u2010adverse\u2010reactions\u2010and\u2010events\u2010blood\u2010and\u2010blood_en. Last accessed 6 Nov 2024."},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2008.02014.x"},{"key":"e_1_2_9_35_1","first-page":"6","article-title":"Blood group systems and antigens described in the last 20\u2009years: an update","volume":"78","author":"Clark NJ","year":"2024","journal-title":"NZ J Med Lab Sci"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.4103\/0973-6247.106725"},{"key":"e_1_2_9_37_1","unstructured":"NarayanS editor.The 2019 annual SHOT report.2020. Available from:https:\/\/www.shotuk.org\/shot-reports\/annual-shot-report-2019\/. Last accessed 9 Jan 2025."}],"container-title":["Vox Sanguinis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/vox.70068","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T23:45:50Z","timestamp":1757547950000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/vox.70068"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,3]]},"references-count":36,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["10.1111\/vox.70068"],"URL":"https:\/\/doi.org\/10.1111\/vox.70068","archive":["Portico"],"relation":{},"ISSN":["0042-9007","1423-0410"],"issn-type":[{"type":"print","value":"0042-9007"},{"type":"electronic","value":"1423-0410"}],"subject":[],"published":{"date-parts":[[2025,8,3]]}}}